Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy
IMPAX receives approval for generic Claritin Reditabs
October 27th, 2003
IMPAX Laboratories, Inc., (IPXL) announced that the U.S. Food and Drug Administration (FDA) has granted approval to the company's abbreviated new drug application (ANDA) for a generic version of Claritin Reditabs (loratadine orally disintegrating tablets) 10 mg. Schering Plough Corp. markets Claritin Reditabs as an over-the-counter (OTC) drug for the relief of symptoms of seasonal allergic rhinitis (hay fever). According to NDCHealth, U.S. prescription and OTC sales of Claritin Reditabs were over $175 million for the 12 months ended July 31, 2003. "This is our seventh ANDA approval this year," said Larry Hsu, PhD, IMPAX...
Source: Health & Medicine Week (2003-10-27)
|
